Dr. Naqvi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 S. Manchester Blvd
Orange, CA 92868Phone+1 832-909-5763- Is this information wrong?
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Carle Foundation HospitalResidency, Internal Medicine, 2003 - 2006
Dow University of Health SciencesClass of 2001
Certifications & Licensure
TX State Medical License 2007 - 2025
CA State Medical License 2016 - 2025
MA State Medical License 2006 - 2008
IL State Medical License 2003 - 2006
Clinical Trials
Publications & Presentations
PubMed
- HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.Benjamin J Lee, Shawn P Griffin, Jean Doh, Alexandre Chan, Stefan O Ciurea, Deepa Jeyakumar, Angela G Fleischman, Kiran Naqvi, Nicholas R Pannunzio, Susan O'Brien, Piy...> ;European Journal of Haematology. 2024 Mar 1
- 3 citationsA Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and c...Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C Issa, Samuel I Dara, Mahesh Basyal, Li Li, K...> ;Blood Cancer Journal. 2023 Jun 29
- Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses.Marina Konopleva, Courtney DiNardo, Tushar Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena, Tianyu Cai, Xiaoping Su, Anna Skwarska, Veronica Guerra, Vinitha Kuruvill...> ;Research Square. 2023 Feb 23
- Join now to see all
Abstracts/Posters
- A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS)Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)Kiran Naqvi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).2019 ASCO Annual Meeting - 6/1/2019
- Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
Press Mentions
Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast PhaseDecember 2nd, 2017
Hospital Affiliations
UCI HealthOrange, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
